Literature DB >> 28059509

Pyrimidinyl Biphenylureas: Identification of New Lead Compounds as Allosteric Modulators of the Cannabinoid Receptor CB1.

Leepakshi Khurana1, Bo-Qiao Fu2, Anantha L Duddupudi2, Yu-Hsien Liao1, Sri Sujana Immadi2, Debra A Kendall1, Dai Lu2.   

Abstract

The allosteric modulator 1-(4-chlorophenyl)-3-(3-(6-(pyrrolidin-1-yl)pyridin-2-yl)phenyl)urea (n class="Chemical">PSNCBAM-1, 2) bound the cannabinoid receptor 1 (CB1) and antagonized G protein coupling. This compound demonstrated potent anorectic effects similar to the CB1 antagonist rimonabant that once was marketed for the treatment of obesity, suggesting a new chemical entity for the discovery of antiobesity drugs. To increase structural diversity of this class of CB1 ligands, we designed and synthesized two classes of novel analogues, in which the pyridine ring of 2 was replaced by a pyrimidine ring. These positively modulate the binding of the CB1 orthosteric agonist CP55,940 while exhibiting an antagonism of G-protein coupling activity. Interestingly, compounds 7d and 8d demonstrated ERK1/2 phosphorylation mediated via β-arrestin unlike the orthosteric CP55,940 that does so in a G protein-dependent manner. These can serve as new lead compounds for the future development of CB1 allosteric modulators that show biased agonism and potentially antiobesity behavior via a new mechanism.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28059509      PMCID: PMC5724760          DOI: 10.1021/acs.jmedchem.6b01448

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  41 in total

Review 1.  The endocannabinoid system: a general view and latest additions.

Authors:  Luciano De Petrocellis; Maria Grazia Cascio; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

Review 2.  Cannabinoid receptors as therapeutic targets.

Authors:  Ken Mackie
Journal:  Annu Rev Pharmacol Toxicol       Date:  2006       Impact factor: 13.820

Review 3.  G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms.

Authors:  Thomas M Bridges; Craig W Lindsley
Journal:  ACS Chem Biol       Date:  2008-07-25       Impact factor: 5.100

4.  Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current.

Authors:  D Gebremedhin; A R Lange; W B Campbell; C J Hillard; D R Harder
Journal:  Am J Physiol       Date:  1999-06

5.  Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin.

Authors:  Francis S Willard; Denise Wootten; Aaron D Showalter; Emilia E Savage; James Ficorilli; Thomas B Farb; Krister Bokvist; Jorge Alsina-Fernandez; Sebastian G B Furness; Arthur Christopoulos; Patrick M Sexton; Kyle W Sloop
Journal:  Mol Pharmacol       Date:  2012-08-28       Impact factor: 4.436

6.  CNS and antimalarial activity of synthetic meridianin and psammopemmin analogs.

Authors:  Matthew D Lebar; Kristopher N Hahn; Tina Mutka; Patrick Maignan; James B McClintock; Charles D Amsler; Alberto van Olphen; Dennis E Kyle; Bill J Baker
Journal:  Bioorg Med Chem       Date:  2011-08-22       Impact factor: 3.641

7.  Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture.

Authors:  J Mu; S Y Zhuang; M T Kirby; R E Hampson; S A Deadwyler
Journal:  J Pharmacol Exp Ther       Date:  1999-11       Impact factor: 4.030

8.  PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats.

Authors:  J G Horswill; U Bali; S Shaaban; J F Keily; P Jeevaratnam; A J Babbs; C Reynet; P Wong Kai In
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

9.  Effects of the cannabinoid CB₁ receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and methamphetamine-seeking behavior in rats.

Authors:  Li Jing; Yanyan Qiu; Yanan Zhang; Jun-Xu Li
Journal:  Drug Alcohol Depend       Date:  2014-08-17       Impact factor: 4.492

10.  Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor.

Authors:  Fabricio A Pamplona; Juliano Ferreira; Octávio Menezes de Lima; Filipe Silveira Duarte; Allisson Freire Bento; Stefânia Forner; Jardel G Villarinho; Luigi Bellocchio; Luigi Bellochio; Carsten T Wotjak; Raissa Lerner; Krisztina Monory; Beat Lutz; Claudio Canetti; Isabelle Matias; João Batista Calixto; Giovanni Marsicano; Marilia Z P Guimarães; Reinaldo N Takahashi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-12       Impact factor: 11.205

View more
  14 in total

1.  The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice.

Authors:  Elizabeth A Cairns; Anna-Maria Szczesniak; Alex J Straiker; Pushkar M Kulkarni; Roger G Pertwee; Ganesh A Thakur; William H Baldridge; Melanie E M Kelly
Journal:  J Ocul Pharmacol Ther       Date:  2017-07-18       Impact factor: 2.671

Review 2.  Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.

Authors:  Leepakshi Khurana; Ken Mackie; Daniele Piomelli; Debra A Kendall
Journal:  Neuropharmacology       Date:  2017-05-17       Impact factor: 5.250

3.  Assessing Allosteric Modulation of CB1 at the Receptor and Cellular Levels.

Authors:  Caitlin E Scott; Debra A Kendall
Journal:  Methods Enzymol       Date:  2017-07-05       Impact factor: 1.600

4.  Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist.

Authors:  Pankaj Pandey; Kuldeep K Roy; Robert J Doerksen
Journal:  J Biomol Struct Dyn       Date:  2019-02-05

5.  Pyrimidinyl Biphenylureas Act as Allosteric Modulators to Activate Cannabinoid Receptor 1 and Initiate β-Arrestin-Dependent Responses.

Authors:  Caitlin A D Jagla; Caitlin E Scott; Yaliang Tang; Changjiang Qiao; Gabriel E Mateo-Semidey; Guillermo A Yudowski; Dai Lu; Debra A Kendall
Journal:  Mol Pharmacol       Date:  2018-10-15       Impact factor: 4.436

Review 6.  Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity.

Authors:  Rachel Dopart; Dai Lu; Aron H Lichtman; Debra A Kendall
Journal:  Drug Metab Rev       Date:  2018-01-21       Impact factor: 4.518

7.  Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution.

Authors:  Thuy Nguyen; Nadezhda German; Ann M Decker; Tiffany L Langston; Thomas F Gamage; Charlotte E Farquhar; Jun-Xu Li; Jenny L Wiley; Brian F Thomas; Yanan Zhang
Journal:  J Med Chem       Date:  2017-08-18       Impact factor: 7.446

Review 8.  Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts.

Authors:  Eric A Wold; Jianping Chen; Kathryn A Cunningham; Jia Zhou
Journal:  J Med Chem       Date:  2018-08-28       Impact factor: 7.446

Review 9.  Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor.

Authors:  Dai Lu; Sri Sujana Immadi; Zhixing Wu; Debra A Kendall
Journal:  Acta Pharmacol Sin       Date:  2018-10-17       Impact factor: 6.150

10.  Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids.

Authors:  Thuy Nguyen; Thomas F Gamage; Ann M Decker; David B Finlay; Tiffany L Langston; Daniel Barrus; Michelle Glass; Danni L Harris; Yanan Zhang
Journal:  Bioorg Med Chem       Date:  2021-05-12       Impact factor: 3.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.